WhiteLab Genomics has closed a $26 million Series B financing round to support preclinical testing of genetic payloads and gene delivery technologies, alongside expansion of its international operations.
AVP led the round, with participation from new investors Yaday Health and Blast Club and existing investors Omnes and Debiopharm. François Robinet, AVP’s managing partner, and Dr. Daniel Teper, managing partner of Yaday Health and founder and CEO of NAYA Therapeutics, have joined WhiteLab’s board.
Founded in 2019 and accelerated through Y Combinator, WhiteLab uses AI to help drug developers select genetic material and determine how to deliver it to specific cells. Its ALFRED platform analyzes biological data to identify targets and design therapeutic components, including payloads and delivery systems.
"The goal is to build a portfolio of experimentally validated bio-assets that WhiteLab can advance independently and with biopharma partners," the company said in a statement. It also intends to strengthen its Boston operations and expand its presence on the U.S. West Coast and in Europe, Japan and South Korea.
"AI can help us design better genomic medicines, but what ultimately matters is whether those designs work in living systems," David Del Bourgo, cofounder and CEO of WhiteLab Genomics, said in a statement. "We have already presented compelling results. This financing allows us to scale that work across multiple delivery technologies and payloads, build a portfolio of validated bio-assets and bring them to biopharma partners around the world."
WhiteLab previously raised $10 million in Series A funding in 2022, with plans to expand its research and development team and U.S. operations.
Another company developing AI-enabled gene delivery technologies is Dyno Therapeutics, whose capsid technology helps developers target the brain, eye and muscle. Dyno expanded its Roche collaboration in October 2024, securing $50 million upfront. In January 2025, Roche exercised an option to license a Dyno vector for an undisclosed neurological disease, resulting in a $7 million payment. Dyno raised $100 million in Series A funding in 2021.
Click here for the original news story.
